Portfolio
Portfolio
Vinivia AG – Do it LIVE
Vinivia AG is one of the leading Swiss providers of live streaming technology for major events, e-commerce and content creation.
In times of global digitalization and covid pandemic, the consumer behavior of all generations has changed permanently. Online shopping is breaking new records year after year and has long since replaced retail at the top. Well-known personalities or brand ambassadors in social media have become indispensable in the marketing of large companies. Online streaming via Netflix or Amazon Prime is rapidly replacing radio and television. Major events such as trade fairs, concerts or sporting events are nowadays hardly imaginable without live streaming.
With its large-scale production studios in Zug/SUI and Cologne/GER, Vinivia also offers its customers the opportunity to produce their livestream under optimal conditions.
ith its services and technology, Vinivia AG serves world-renowned customers such as Johnson&Johnson, Nasdaq, Coca-Cola, UEFA, Toyota, Audi, CNN, NBC, Tommy Hilfiger, as well as Swiss customers such as Swisscom and SRF.
For further information please visit the company's homepage, or contact us directly.
TOPADUR Pharma AG – enhancing quality of life
TOPADUR’s vision is to improve the quality of life of patients by providing highly effective and safe medicines, with a focus on wound healing and preservation of vision.
Ageing processes are characterised by a reduction in blood circulation and a dysregulation of cell to cell communication. An imbalance of cGMP levels leads to diseases such as chronic wounds, skin fibrosis, glaucoma, colon cancer, hair loss and skin ageing.
TOPADUR has discovered new compounds and is developing drugs that target the cGMP enzyme regulatory system. The compounds regulate the activity of sGC and PDE5 enzymes to increase cGMP levels. This ultimately enables blood flow and corrects inadequate cell to cell communication.
In addition to annual placements in the top 100 Swiss start-ups in recent years – and winning the Venture Leaders in Life Science Award in 2016 – the company has been awarded various CTI grants and Innosuisse grants. TOPADUR Pharma AG was also able to recruit Dr Daniel L. Vasella as a new member of its Board of Directors.
For further information, please visit the company’s homepage, or contact us directly.
Exploris Health AG
After its foundation, Exploris started as a data analysis service company. In collaboration with Basel University Hospital, the company developed a novel, non-invasive AI test for the early detection of coronary heart disease. Exploris is one of the first companies with AI-based diagnostic and therapeutic solutions which have been validated in three clinical trials with over 2,000 patients.
Its "Cardio Explorer" product is an AI-based test that detects patients with potentially life-threatening coronary stenosis and thus helps in the prevention of heart attacks. The "Cardio Explorer" is easy to use and very reliable. It provides general practitioners and cardiologists in private practice with a test that detects stenoses with the same accuracy as is otherwise only possible in a hospital using a CT or MRI. This test has been registered by the European regulatory authority and is already being used in the marketplace.
Exploris won the Biolabs Prize Switzerland 2018 and is financially supported by the EU, the Swiss Confederation and the Canton of Zurich.
For further information, please visit the company’s homepage, or contact us directly.
CUTISS AG – personalized skin
CUTISS AG is an innovative Swiss life science company that aims to provide patients suffering from large and deep skin defects with the first automated personalised skin tissue therapy called denovoSkin™, a safe, effective and accessible therapy for children and adults.
Millions of people worldwide suffer from severe skin defects that require surgical treatment in order to restore skin function.
After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG is able to biotechnologically produce personalised and large-scale skin grafts (denovoSkin™) starting from a small biopsy from a patient’s healthy skin.
The company won the Top 100 Swiss Startup Award in 2020, having been in the top 10 in each of the previous two years, and was also awarded the 2019 Swiss Technology Award. For further information, please visit the company’s homepage, or contact us directly.
Securecell AG – do well by doing good
Securecell AG is a high-tech life science company with platform technologies for bioprocesses in biopharmaceuticals as well as for relevant breakthrough applications in medical technology.
In the biotech sector, Securecell sells proprietary software and hardware solutions for fully automated cell cultivation and process monitoring for a large number of multinationals in the pharmaceutical and food industries. The company has more than 25 years of experience in this field.
In the medtech field, Securecell is working on radically unique and patent-protected innovations that fundamentally change blood glucose measurement and control in intensive care units. They remove the current therapeutic limitations in diabetes treatment through direct communication and interaction with the blood, enabling diabetes patients to live better. Securecell thus has the potential to become the diabetes industry’s "game changer".
For further information, please visit the Securecell AG media portal and the company homepage, or contact us directly.